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Summarv Patients with high-grade astrocytomas have a poor prognosis. However, considerable variation
exists within this group of patients with respect to post-operatis-e survival. In order to determine whether
genetic alterations might be of help in subdividing this group. we used allele loss on chromosomes 10 and 17p
and epidermal growth factor receptor (EGFR) gene amplification in the tumours as genetic parameters and
determined their prognostic value. A series of 47 malignant (grade III and grade IV) tumours were genetically
characterised. and four types of tumours were found. Type 1 tumours had loss of heterozygosity on
chromosome arm 17p (LOH 17p) as the sole genetic alteration. Patients with this type of tumour were
relatively young (mean age 39 years) and had a median survival period of 17 months. Type 2 tumours
displayed only allele loss on chromosome 10 (LOH 10). type 3 tumours had LOH 10 + LOH 17p and type 4
tumours contained LOH 10 + EGFR gene amplification. Patients with types 2. 3 and 4 tumours were older
(mean ages 59. 65 and 54 years respectively) and had a shorter survival (median duration 6. 3 and 2 months
respectively) than type 1 patients. Multisariate analysis indicated that the genetic subdivision was a significant
prognostic sariable. In this study. age prosed to be of minor importance with regard to survival. Our studv
revealed a predominance of frontally located tumours in patients with type I tumours. i.e. with LOH 17p only.
Loss of heterozygosity (LOH) for loci on chromosome 10
and 17p and amplification of the epidermal growth factor
receptor (EGFR) gene on chromosome 7 are the most fre-
quent genetic alterations in human malignant astrocytoma.
LOH 10 is predominantlI associated with high-grade astro-
cvtomas and has been reported to occur in 60-75% of cases
(James et al.. 1988: Fujimoto et al.. 1989: Fults et al.. 1990:
Watanabe et al.. 1990: Venter & Thomas. 1991: Fults et al..
1992). LOH 17p is apparent in 30-35% of astrocytomas of
all malignancy grades (El-Azouzi et al.. 1989; Fults et al..
1989: James et al.. 1989). It is frequently found in association
with mutation of the TP53 gene on 17p (Nigro et al.. 1989:
Chung et al.. 1991: Frankel et al.. 1992: Fults et al.. 1992:
Von Deimling et al.. 1992a). EGFR gene amplification has
been noted in about 40% of high-grade astrocytomas (Wong
et al.. 1987: Bigner et al.. 1988: Ekstrand et al.. 1991). Less
frequent genetic alterations in high-grade astrocytoma in-
clude LOH for loci on chromosomes 13q and 22q. which are
also found in low-grade tumours. and LOH for loci on
chromosomes 9p. lp and 19q (Collins & James. 1993).
Finally. amplification of several proto-oncogenes. including
MYCN. GLI and MDMV2. and the anonymous marker
D17S67 has been noted in a low percentage of high-grade
astrocytomas (Collins & James. 1993: Bijlsma et al.. 1994).
Although. in general. prognosis is poor for patients with
high-grade astrocytoma. considerable variation exists in this
group of patients with respect to post-operative survival. The
genetic alterations found in high-grade astrocytoma might be
of help in defining subsets of tumours that correlate with
clinical outcome. Recently. using LOH 10. LOH 17p and
EGFR gene amplification as genetic parameters. Von Deim-
ling et al. (1993) proposed a genetic subdivision of glioblas-
toma multiforme that correlates with mean age of the
patient. One subset was characterised by the presence of
LOH 17p and the absence of EGFR gene amplification. This
type of tumour was primarily found in younger patients. The
other subset had EGFR gene amplification, but no LOH
17p. and was primarily found in older patients. LOH 10 was
not useful in subdividing the tumours in their study. It is well
documented that for high-grade astrocytoma a negative rela-
tionship exists between advancing age and period of post-
operative survival (Burger & Green. 1987: Salford et al..
1988). Taken together. these data suggest that patients with
LOH 17p but no EGFR gene amplification have a better
prognosis than those with EGFR gene amplification and no
LOH 17p.
The objective of the present study was 2-fold. Firstly. we
wanted to determine whether the genetic subdivision cited
above also applies to the series of high-grade astrocytomas
that we studied. Secondly. considering the strong influence of
age on survival, we wanted to determine whether such a
genetic subdivision has a prognostic significance that is
independent of age.
Materials and methods
Tumour samples
Tumour samples were obtained from patients undergoing
brain surgery at the Academic Medical Centre in Amster-
dam. Two specimens (cases 534 and 543) were obtained from
the Department of Neurosurgery of the University Hospital
of Utrecht. The Netherlands. All tumour samples were
primary lesions that were removed prior to radiotherapy.
Only homogeneous high-grade tumours (grades III and IV)
were used for RFLP (restriction fragment length polymor-
phism) analysis. except for tumour samples 316. 449 and 673.
These samples represent high-grade parts of heterogeneous
high-grade tumours that were previously molecularly
analysed (Leenstra et al., 1992). The molecular data for
tumours 1197. 1672 and 1683 have been published before
(Bijlsma et al.. 1994). For DNA extraction. tumour tissue
samples were quickly frozen in liquid nitrogen and stored at
- 80°C until use. Peripheral venous blood samples were col-
lected prior to surgery. Routine histopathological examina-
tion was performed on H&E- and Gomori-stained sections of
paraffin-embedded blocks of formalin-fixed material and
compared with frozen specimens. Tumours were graded
according to Kernohan and Sayre (1952).
Correspondence: Th.J.M. Hulsebos. Department of Human
Genetics. Academic Medical Centre. Universitv of Amsterdam.
Meibergdreef 15. 1105 AZ Amsterdam. The Netherlands.
Received 5 November 1993; and in revised form 14 March 1994.
Br. J. Cancer (1994). 70. 684-689 (D Macmillan Press Ltd.. 1994GENETIC ALTERATIONS IN ASTROCYTOMA RELATED TO PROGNOSIS 685
Southern blot analysis and DNA sequencing
Procedures for the isolation of DNA from tumour tissue
samples and corresponding blood leucocyte samples. the lat-
ter as source of normal DNA. have been described in detail
previously (Leenstra et al.. 1992). DNA samples were
digested with restriction enzymes according to the manufac-
turer's instructions (Boehringer. Mannheim. Germany). The
resulting DNA fragments were separated in agarose gels and
transferred to nylon membranes (Gene Screen Plus. New
England Nuclear: or Hybond-N+. Amersham). Probes were
3'P labelled bv random oligonucleotide priming (Feinberg &
Vogelstein. 1984) and hybnrdised to the nylon membranes.
Hybnrdisation and washing conditions were as descnrbed
previously (Leenstra et al.. 1992). Sequencing of exons 5-8 in
the TP53 gene was performed by using the procedure des-
cnrbed by Baker et al. (1990).
DNA probes
For LOH analysis the following DNA probes were used.
Chromosome 10: pMHZ15 (DIOS17). H.4IRBP (RBP3).
pVII (ERCC6). p9-12A (DIOS5). pTB1O.163 (DIOS22).
pTB10.171 (DIOS19). pTHH54 (DIOS14). pl-101 (D1OS4).
p4dIII RI 0.55 (D1OS85) and pEFD75 (D1OS25); chromo-
some 17p: pYNZ22.1 (D17S5). pYNH37.3 (D17S28). LEW504
(D117S68). LEW502 (D117S66). pProSP53 (TP53). pHFI2-1
(D17S1). LEW503 (D17S67). LEW403 (D17S63). pVAW-
412R2 (D17S124). EW405 (D17S121). LEW401 (D17S61).
pVAW412R3 (D17S125). pVAW409Rl (D17S122). pUC1O-41
(D17S71) and LEW301 (D17S58). Physical map locations
and RFLPs. identified by these probes. were taken from
Human Gene Mapping 11 (1991). except for probes
pProSP53 (Matlashewski et al.. 1987) and pVII (Troelstra et
al., 1992). D17S121 and D17S124 were considered as a single
locus. because both reside on the same 200 kb Sfi fragment
(Pentao et al.. 1992). D17S61. D17S122 and D17S125 were
also grouped as a single locus. because they all are on a
1.150kb NotI fragment (Matsunami et al.. 1992). In most
cases, the presence or absence of a chromosomal region
could be established by LOH analysis on the basis of at least
two informative markers. Not all markers were tested for
each chromosome (arm).
EGFR gene amplification
EGFR gene amplification was determined by hybridisation of
probe pE7 (Wong et al.. 1987) to Southern blots of EcoRI-
digested paired leucocyte and tumour DNAs and quantita-
tion of the resulting signals. ranging in size from 1 to 8 kbp.
with a Phosphorimager (Molecular Dynamics). Amplification
levels in the tumours were normalised for differences in
sample loading by comparing signal intensities obtained by
hybridising reference probe pDP34 (DXYSI: Human Gene
Mapping 11. 1991) in tumour and corresponding leucocyte
DNA. Amplification in tumour DNA was defined as a nor-
malised amplification level of greater than 5 (cf. Von Deim-
ling et al.. 1992b. 1993).
Clinical data
The clinical data were obtained by reviewing clinical and
out-patient records. Survival data were obtained either from
clinical records or by written information from general prac-
titioners. Following surgerv. all patients were treated accord-
ing to a standardised fractionated radiotherapy protocol
(60 Gy). None of the patients received chemotherapy.
Results
Genetic alterations
The study included 47 high-grade tumours. These were,
according to Kernohan and Sayre (1952). ten grade III and
37 grade IV astrocytomas. For the purpose of this investiga-
tion thev wvere considered as one group because. in the
Kernohan system. patients with grade III and grade IV
tumours do not differ in median post-operative survival
(Scanlon & Taylor. 1979: Daumas-Duport et al.. 1988:
Revesz et al.. 1993). The genetic alterations that were found
and the relevant clinical data of the individual patients are
shown in Table I. LOH for chromosome 10 markers was
detected in 29 (62%) tumours. Most tumours displaved LOH
for all informative markers. indicating loss of a whole copy
of chromosome 10. Deletion of part of chromosome 10 was
apparent in seven tumours. The LOH profile for each of
these tumours is depicted in Figure 1. Recent reports (Ran-
som et al.. 1992: Rasheed et al.. 1992: Fults & Pedone. 1993:
Karlbom et al.. 1993) suggest the presence of at least three
regions of common deletions on chromosome 10. i.e. in the
telomeric part of 10p and in the centromeric and telomeric
parts of 10q. However. excluding tumour 1208. our series of
tumours with partial deletions indicates that the central
region of chromosome 10. between loci D10S17 and D10S85.
is critical for astrocytoma tumorigenesis. In tumour 1208.
allele loss was restricted to the telomeric 10q marker
DlOS285. which is most probablv outside the critical region
(cf. Ransom et al.. 1992: Rasheed et al.. 1992: Fults &
Pedone. 1993). For this reason. case 1208 was considered as
having no LOH for the critical region on chromosome 10 in
the statistical analysis that follows.
LOH for chromosome arm 17p A-as found in 15 (32%)
tumours. The LOH data for nine tumours suggested loss of
the whole p arm. In the remaining six tumours deletions of
part of chromosome 17p were seen. Except for tumour 314.
the deletion in all these tumours included the tumour-
suppressor gene TP53 in chromosomal band 17pl3.1. Both
copies of the TP53 gene were retained in tumour 314. This is
demonstrated in Figure 2. Figure 2a shows hybridisation of
the TP53 cDNA probe pProSP53 to BglII-digested tumour
and coresponding leucocyte DNA. The 12 and 9kb allelic
fragments remain in the tumour. Figure 2b shows the same
Southern blot. but in this case hybridised with probe
LEW502. identifying locus D17S66. which is distal to TP53
in chromosomal band 17plI3.1. The 2.5 kb allele at locus
D17S66 is clearly absent in the tumour. LOH was also found
at D17S68 in chromosomal band 17pl3.2 but not at ten
other informative loci on 17p. including D17S5 and D17S28
at the tip of 17p (data not shown). We could not detect any
sequence abnormality in exons 5-8 of the TP53 gene. in
which most of the known TP53 gene mutations have been
found (Hollstein et al.. 1991). Therefore. as the interstitial
deletion in tumour 314 most probably did not affect the
TP53 gene. the tumour was considered as having no LOH
17p for the TP53 gene region in the statistical analysis that
follows. The deletion of both copies of the TP53 gene in
tumour 1197 and LOH for the TP53 gene region in tumour
1672 have been reported previously (Bijlsma et al.. 1994).
Significant EGFR gene amplification (more than five times the
level in normal tissue) wsa seen in nine (19%) tumours.
Amplification levels ranged from eight to 33 times (Table I).
Although EGFR gene amplification is usually found in a
higher proportion of high-grade astrocytomas. a similar low
percentage has been reported in another study (Venter &
Thomas. 1991). In accordance with earlier observations (Von
Deimling et al.. 1992b). EGFR gene amplification almost
exclusively (in eight of nine cases) occurred in tumours that
also displayed LOH 10.
Genetic alterations in relation to patients'age at operation
Based on the genetic alterations presented in Table I. we
defined four groups of patients. These were patients with
only LOH 17p (n = 7). with only LOH 10 (n = 14). with
LOH 10+ LOH 17p (n = 6) and with LOH 10+ EGFR gene
amplification (n = 7). Two patients with genetic alterations
(cases 1672 and 1683) did not fit into any of these groups
and were excluded from further analysis. Eleven patients had
none of the studied genetic alterations in their tumours.
The mean age of each group of patients is given in Table686 S. LEENSTRA et al.
Table I Clinical and genetic data. Cases with similar combinations of genetic alterations have been
grouped
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R tp
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1
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1
60
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1
1
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0.5
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1
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0.3
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NA
0.3
6
l
NA
0.5
0.5
2
4
1
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48
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NA
1
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6
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NA
8
1
30
4
26
10
2
6
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6
16
4
3
0.5
3
1
11
2
2
0.2
4
5
11
1
6
(16)
6
7
0.5
19
2
(27)
4
9
3
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(6)
- (3)
- (4)
- (4)'
- (7)
(2)
- (3)
+ (4)
+ (5)
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+ (5)
+ (3)d
+ (3)
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(2)
(2)
- (4)
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+ (6)
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+ (4)
+ (3)b
+ (4)b
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+ (3)
+ (3)b
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(6)
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(6)
- (9)
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(4)
(3)
(5)
(2)'
(6)
(5)
(7)
(5)
(6)
(6)
(2)
(6)
+
+
+
+
+
+
+
+
+
Clinical data: Local, tumourlocation: f,frontal; p,parietal; t, temporal; o,occipital; th,thalamus; b, basal,c. cerebellum. DUR, duration of symptoms in months. SURV, post-operative survival time in months; survival time between brackets indicates that the patient was alive at closure of the study. NA, data not
available.
Genetic data (number ofinformative markers between brackets): 'Normaised amplification levels of 12, 11,26,8,33, 11, 15, 15in tumours449, 858, 890,891,893, 1194, 1666, 1683 respectively. bDeletion ofpart of
chromosomearm 17p,includingtheTP53 generegion. 'DeletionofD1OS25 innon-critical region(Figure 1). dDeletion ofpart ofchromosome 10 (Figure 1). 'Deletion ofpart ofchromosome arm 17p, not including the
TP53 gene region (Figure 2).
II. The Student-Newman-Keuls multiple range test revealed
a difference between the group of patients showing only
LOH 17p and the other three groups. The mean age of these
three groups did not differ significantly.
Genetic alterations in relation topost-operative survival
Kaplan-Meier survival curves were constructed for the four
groups of patients (Figure 3). The median survivals are given
in Table II. The survival curves were compared by log-rank
test. The resulting P-values were adjusted for multiple com-
parisons by the procedure of Hommel (see Wright, 1992).
The difference in median survival between the group of
patients with only LOH 17p and the group of patients with
LOH 10 or with LOH 10+ LOH 17p was marginally
significant (P-values of 0.055 and 0.072 respectively). The
difference in survival between the LOH 17p only patients and
the patients with LOH 10+ EGFR gene amplification was
significant (P = 0.039). The groups of patients with LOH 10
only, LOH 10 + LOH 17p and LOH 10 + EGFR gene amplification did not differ significantly in median survival
between each other (P-value for each comparison>0.17).
Genetic alterations in relation to other clinical data
All tumours (n = 7) with LOH 17p and no other genetic alterations occupied a frontal (frontal or frontoparietal) posi- tion (Table I). This suggests a significant (P<0.0001, x2 test)
predominance of frontally located tumours in the group of
patients with LOH 17p as the sole genetic alteration in the
tumour.GENETIC ALTERATIONS IN ASTROCYTOMA RELATED TO PROGNOSIS 687
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Figure I Loss of heterozygosity (LOH) analysis of high-grade
astrocytomas with deletions of part of chromosome 10. 0, LOH.
0. no LOH; 0, not informative.
a
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Multivariate analysis
The variables age, grade, duration of symptoms, tumour
location, extent of tumour resection and genetic subdivision
were analysed for prognostic significance by univariate
analysis. The variables grade, duration of symptoms, tumour
location and extent of tumour resection did not reach
significant levels in this analysis. To explore the effect of age
and genetic subdivision on survival, Cox's regression model
was used. Elimination of the genetic subdivision was a
significant step (P = 0.026); elimination of age was not
significant (P = 0.17).
By using LOH 10, LOH 17p and EGFR gene amplification
as genetic parameters, we have subdivided our senres of high-
grade astrocytomas into four types. Type 1 has LOH 17p
without concurrent genetic changes, type 2 has LOH 10 as
the sole genetic alteration, type 3 is characterised by both
LOH 10 and LOH 17p and type 4 is characterised by LOH
10 and EGFR gene amplification. The mean age at operation
was significantly lower for the patients with the type 1
tumours than for the patients with types 2, 3 and 4 tumours
(Table IL). Using the same genetic parameters, Von Deimling
et al. (1993) proposed a different subdivision for glioblas-
tomas multiforme into two types. Their type 1 tumours had
LOH 17p and no EGFR gene amplification and occurred
primarily in younger patients. Their type 2 tumours had
EGFR gene amplification and no LOH 17p and occurred
primarily in older patients. In the system of Von Deimling et
al., the type 1 tumours included those with only LOH 17p
and those with both LOH 17p and LOH 10. The mean age
of their type 1 patients was 40.5 years. In our study, both
genetic variants could not be grouped together. We detected
a significant age difference between our type 1 patients (only
LOH 17p) and our type 3 patients (LOH 10 + LOH 17p), i.e.
39 vs 65 years. A possible explanation for this discrepancy is
the relatively small number of tumours that was analysed in
both studies. Another explanation may be that both series of
._
0
C.co
Figure 2 RFLP analysis at loci TP53 and D17S66 in tumour
314. Tumour (T) and corresponding blood leucocvte (L) DNAs
were digested with BgilII. The resulting fragments were separated
in an 0.8% agarose gel, transferred to a nylon filter and hy-
bridised with pProSP53 (TP53, a). After removal of the signal.
the filter was rehybridised with LEW502 (D17S66. b). Sizes of
restriction fragments are given in kbp.
Survival in months
Fgre 3 Kaplan-Meier survival curves for patients whose
tumours contained only LOH 17p (U. type 1). only LOH 10 (-
-. type 2). LOH 10 + LOH 17p ( . type 3) or LOH
10 + EGFR gene amplification ( -. tWpe 4).
Table 11 Mean ageat operation and mediansurvivalperiod forgroups ofpatients
defined by genetic alterations in the tumour
Mean age Median survival
Genetic group n (Years} (months)
LOH 17p 7 39 (25-51) 17 (6-31 or greater)
LOH 10 14 59 (42-74) 6 (1-30)
LOH l0+LOH 17p 6 65(59-71) 3 (0.5-11)
LOH 10 + EGFR amplification 7 54(44-69) 2 (0.2-11)
15
14
13
12
11.2
11.2
21
22
23
24
25
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tumours do not match completely because of the different
grading systems that were used (glioblastomas multiforme
and grade III + IV astrocytomas).
Our type 1 patients differed from the type 2. 3 and 4
patients with regard to their median surv,ival time. although
the difference was only significant (P = 0.039) between the
type 1 and type 4 patients (Table II and Figure 3). Type 1
patients differ from the type 2. 3 and 4 patients in mean age
at operation. and age is an important variable with regard to
survival (Burger & Green. 1987: Salford et al.. 1988).
Therefore. the longer survival in the type 1 patients could be
explained by their younger age. However. multivariate
analysis revealed that. after allowing for age. the genetic
subdivision remained a variable with prognostic significance.
In this analysis, age was assumed to be linearly related to the
logarithm of the hazard rate. If this assumption is not cor-
rect. then. owing to the lack of overlap in age between the
type 1 patients and the other groups of patients. no adjust-
ment for age would be possible.
Comparable studies with regard to survival in patients with
high-grade astrocytomas and with the same set of genetic
alterations have, to our knowledge. not been published.
Bigner et al. (1988) studied EGFR gene amplification in
malignant gliomas but could not detect a significant effect on
median survival. In contrast to this, Hurtt et al. (1992)
reported a significant and age-independent decrease in
median survival in patients with EGFR gene amplification. If
we consider EGFR gene amplification as an independent
variant in Cox's regression model. then it has age-corrected
prognostic significance (P = 0.004). However, as noted by
Von Deimling et al. (1992b) and as shown in Table I. EGFR
gene amplification is strongly associated with LOH 10. Our
type 4 patients with LOH 10 + EGFR gene amplification had
a similar mean age to the type 2 patients with LOH 10 onlv
(59 and 54 years respectively). The difference in survival
between both groups of patients is not significant (P = 0.17).
thereby questioning the prognostic importance of EGFR
gene amplification. Thus, the contradictory reports on the
prognostic importance of EGFR gene amplification could be
caused by differences in the chromosome 10 status of the
tumours that were examined. In all our type 1 patients. the
tumour occupied a frontal position. As noted before, these
patients were relatively young at presentation and had a
favourable prognosis. This observation genetically supports
other clinical studies reporting a longer sur'Vival time for
patients with frontally located lesions (North et al.. 1990;
Curran et al., 1992; Ayoubi et al.. 1993).
In summary. our data suggest that histopathologicallv
high-grade astrocytomas constitute a genetically hetero-
geneous group of tumours. They can be subdivided by using
allele loss on chromosomes 10 and 17p and EGFR gene
amplification as genetic parameters. The genetic subdiv%ision
into four types correlates with mean age and median survival
of the different groups of patients. Under certain assump-
tions, the genetic subdivision has major prognostic sig-
nificance. The discrepancies between the results presented
here and those of others may in part be explained bv the
small sample sizes in the studies.
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